New Bacteria, and Two Potential Antibiotics, Discovered in Soil
Posted3 months agoActive3 months ago
rockefeller.eduResearchstoryHigh profile
excitedpositive
Debate
60/100
AntibioticsAntibiotic ResistanceMicrobiology
Key topics
Antibiotics
Antibiotic Resistance
Microbiology
Researchers have discovered hundreds of new bacteria and two potential antibiotics in soil, sparking discussion on the potential to combat antibiotic resistance and the challenges of developing new treatments.
Snapshot generated from the HN discussion
Discussion Activity
Very active discussionFirst comment
2m
Peak period
58
Day 1
Avg / period
21.3
Comment distribution64 data points
Loading chart...
Based on 64 loaded comments
Key moments
- 01Story posted
Sep 24, 2025 at 12:03 PM EDT
3 months ago
Step 01 - 02First comment
Sep 24, 2025 at 12:05 PM EDT
2m after posting
Step 02 - 03Peak activity
58 comments in Day 1
Hottest window of the conversation
Step 03 - 04Latest activity
Oct 6, 2025 at 2:24 AM EDT
3 months ago
Step 04
Generating AI Summary...
Analyzing up to 500 comments to identify key contributors and discussion patterns
ID: 45362254Type: storyLast synced: 11/20/2025, 3:53:09 PM
Want the full context?
Jump to the original sources
Read the primary article or dive into the live Hacker News thread when you're ready.
Welllll that doesn’t sound like a great idea
The two prospects:
Erutacidin, disrupts bacterial membranes through an uncommon interaction with the lipid cardiolipin and is effective against even the most challenging drug-resistant bacteria.
trigintamicin, acts on a protein-unfolding motor known as ClpX, a rare antibacterial target
The difficulty with bacterial DNA is that they have common elements and actively share DNA to boot. Sequencing only short sections make genome assembly unreliable. 200x longer sequences makes much more accurate genomes.
Then even if you find genes, we can't usually culture enough bacteria to make the product (typically instead injecting the sequences into bacteria we can culture). So being able to make the product without culturing the organism is key.
> So being able to make the product without culturing the organism is key.
No, it isn't. The article talks about using chemical synthesis, rather than using a biological platform to express the product via genes.
"To convert the newly uncovered sequences into bioactive molecules, the team applied a synthetic bioinformatic natural products (synBNP) approach. They bioinformatically predicted the chemical structures of natural products directly from the genome data and then chemically synthesized them in the lab. With the synBNP approach, Brady and colleagues managed to turn the genetic blueprints from uncultured bacteria into actual molecules—including two potent antibiotics."
https://asm.org/articles/2023/june/hunting-for-antibiotics-i...
I have a kidney transplant and use two of these medications daily.
Tacrolimus was discovered in 1987 by a Japanese team led by pharmacologist Tohru Kino; it was among the first macrolide immunosuppressants discovered, preceded by the discovery of rapamycin (sirolimus) on Rapa Nui (Easter Island) in 1975.[45] It is produced by a soil bacterium, Streptomyces tsukubensis.[46] The name tacrolimus is derived from "Tsukuba macrolide immunosuppressant".[47]
https://en.m.wikipedia.org/wiki/Tacrolimus
When you study organic synthesis, these kinds of structures are the Holy Grail. Sometimes it takes dozens of steps, and an overall yield of just a few percent to make them synthetically.
Because so much of 20th-century drug research happened in the US (because the US had capitalism) the clinical-trials requirement and the Drug War there had an outsized effect, and other countries copied them afterwards.
One particular case that I studied was Zasloff's "magainin": https://en.wikipedia.org/wiki/Magainin which was denied licensing even though the clinical trials found that it was both safe and effective. The problem was that it wasn't more effective than the existing standard of care; it was only equally effective.
It seems certain that the Kefauver–Harris Drug Act has prevented innumerable cases of useless or harmful drugs from being marketed. But, looking at the history of drug development, it also seems clear that the rapid drug development in the decades up to 01962 virtually halted at that time, and the absence of the drugs that would have been discovered since then has surely killed many more people than the inadvertent use of harmful drugs ever could have.
People who suffer from unexplained / untreatable diseases like arthritis or MS might get some relief, while there would be an added pressure on the pharma industry to innovate in antibiotic development by accelerating the loss of existing antibiotic efficacy through the evolution of resistance.
You want to cause current antibiotics to be less useful so pharma will invest more? Just allow generic versions.
If you want to pressure the pharma industry use laws.
Some antibiotics do have a good enough safety profile that such occasional speculative use would be a good tradeoff. Elderly people are also the one group least able to handle infections! Others do not.
This is another one of those schemes for getting a bunch of people killed in the service of medical crankery, isn't it.
You're joking, right?
Total antibiotic resistance is what we're trying to minimise, remember. You're proposing to achieve that in the long term by making it worse in the short term, but the only way that makes sense is if there is actually an abundance of new antibiotics "out there" waiting to be discovered, and the binding constraint currently limiting their development is that pharmaceutical companies can't be bothered researching them. But that is obviously not true -- steadily growing resistance has raised alarm for decades, and any pharma company that could produce a genuinely new antibiotic today would make immediate bank.
IOW, the incentives are already there and they aren't helping, so why take the extra step of making things deliberately worse?
That is misleading. When a clinical trial is designed for non-inferiority, it doesn't say anything about being superior or equal. Just as legally, a defendant is either guilty or not guilty - there is no legal adjudication of being "innocent".
These drugs are not comparable (different stability profiles, different mechanisms of action, etc) and to say they're equal is highly misleading.
>and the absence of the drugs that would have been discovered since then has surely killed many more people than the inadvertent use of harmful drugs ever could have.
There is no evidence that safety regulations have denied us some miracle drug. I don't want the FDA approving drug products that are harmful to the general population. You haven't made a good argument for "the greater good" besides a reference to magainin, a product for topical treatment of foot ulcers. There are thousands of known anti microbial peptides.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7937881/
Well, of course we don't know of a specific miracle drug they've denied us, because it isn't until after a drug is in wide use that you find out whether it's a miracle drug or not. But we can see that there were enormous numbers of miracle drugs in the 20 years immediately preceding the safety regulations, and almost none in the 63 years since then. There have definitely been some† but a very large slowdown is clearly evident if you look at the history. Most of even the important new drugs since then are slight variations on previously known molecules.
A reasonable inference from these observations is that safety regulations have denied us a lot of miracle drugs.
______
† zidovudine, Paxlovid, oral rehydration therapy, ivermectin, propofol, SSRIs, sildenafil, acyclovir, misoprostol, ritonavir, and arguably buprenorphine come to mind; and time will tell whether lovastatin and semaglutide belong on this list or on the failures list with fen/phen and heroin.
Maybe you disagree, but I don't think infliximab or even rituximab is close to the same level of importance as things like penicillin, Thorazine, misoprostol, or oral rehydration therapy. Insulin is, and it's technically a biological, but it was pre-01962.
I listed the three antivirals I think were revolutionary rather than evolutionary (all of which were post-01962), and I did list lovastatin, which was the first statin available, and widely applicable, and therefore the revolutionary one.
Everyone? That's not an unusual position by any means. It's known as the Hygiene Hypothesis.
https://en.wikipedia.org/wiki/Hygiene_hypothesis
Now the first guy who decided to try to treat an infected wound with mold... something's wrong with that guy, but that's the nice thing about having a lot of us trying all sorts of goofy stuff. Sometimes crazy turns out to be right!
> Many victims rapidly developed an especially viscous pneumonia and then, as one physician put it, “died struggling to clear their airways of a blood-tinged froth that sometimes gushed from their nose and mouth.” Medical science of the day was helpless before the onslaught. There was nothing Nelle’s doctor could do for her. Jack, who ordinarily attended mass on an intermittent basis, began lighting candles daily at the altar. The boys hovered anxiously, waiting for the doctor to pronounce the end. Instead, in desperation, he advised the family to feed her as much moldy cheese as she could stomach. There is no medical reason that a virus would respond to what the doctor may have supposed was a crude form of antibiotic. But Nelle recovered nonetheless, her indomitable will refusing to submit to a mere pathogen. For the rest of his life, my father would credit the cheese.
https://youtu.be/X29lF43mUlo?t=160
There is a similar concept for that kind of saying called the "hygiene hypothesis" though, but it's often taken too far to the extremes from what it's trying to claim.
Turns out that growing infectious bacteria is a usually easier since they often grow in rich/meat broths at body temperatures.
A few years ago a group at Northeastern developed a device that allows single bacteria/colonies to be isolated while still in indirect contact with the soil.
https://en.wikipedia.org/wiki/Isolation_chip
In situ cultivation of previously uncultivable microorganisms using the ichip https://www.nature.com/articles/nprot.2017.074 https://sci-hub.ru/10.1038/nprot.2017.074
Looks like they patented it, not sure if others are working on similar things.
To better answer your question, the inventor of the device has his own theories as to why this happens (although I like my idea better)..
The phenomenon of microbial uncultivability https://www.sciencedirect.com/science/article/abs/pii/S13695...
Now, it'd be nice to keep those for as long as possible. Is regulation on the use of these feasible? I'd think that if your law just restricts its use on animals (which I believe is where the majority of antibiotic-resistance comes from) that would be easier to pass than if you tried to restrict its use on humans, but I don't know if there's precedent for it.
Good news if true. Antibiotics seem to be a bit of a Tragedy of the Commons situation though; my intuition is that people should do this but probably won't.
Not solved, but it makes antibiotic resistance look more like our generations Killer Bees.
There's also now strong documented history of bacteria losing resistances over time hence the rotating strategy. Granted, some resistances are "cheap" to maintain and not lost, or recirculated in the wild and it's not a panacaea (it's more a hypothesized strategy than a realized one and it hasn't solved the issue), but it's by no means a failure to understand evolutionary principles.
https://www.nature.com/articles/s41587-025-02810-w
One of the antibiotics targets a protein that is also essential in mitochondria, so it's not a good candidate for a drug. The other targets bacterial cell membranes and showed no resistance developing, which seems more promising.